Gene · 3623
Papers1,777
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 1,777
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Recent biological applications of heterocyclic hybrids containing s-triazine scaffold. | RSC Adv | 2023 | 37854486 | PubTator, text mining | PubMed |
| Drug-Tolerant Mycobacterium tuberculosis Adopt Different Survival Strategies in Alveolar Macrophages of Patients with Pulmonary Tuberculosis. | Int J Mol Sci | 2023 | 37834390 | PubTator, text mining | PubMed |
| Biodegradation of Inosine and Guanosine by Bacillus paranthracis YD01. | Int J Mol Sci | 2023 | 37833910 | PubTator, text mining | PubMed |
| Comprehensive analysis of cuproptosis and copper homeostasis genotyping and related immune land scape in lung adenocarcinoma. | Sci Rep | 2023 | 37783723 | PubTator, text mining | PubMed |
| Design, synthesis, in vitro and in silico evaluation of novel substituted 1,2,4-triazole analogues as dual human VEGFR-2 and TB-InhA inhibitors. | Bioorg Chem | 2023 | 37774433 | PubTator, text mining | PubMed |
| A novel risk model of three gefitinib-related genes FBP1, SBK1 and AURKA is related to the immune microenvironment and is predicting prognosis of lung adenocarcinoma patients. | Aging (Albany NY) | 2023 | 37737707 | PubTator, text mining | PubMed |
| Synthesis and Structure-Activity Relationships of a New Class of Oxadiazoles Targeting DprE1 as Antitubercular Agents. | ACS Med Chem Lett | 2023 | 37736177 | PubTator, text mining | PubMed |
| CRISPR/Cas9-mediated activation of NR5A1 steers female human embryonic stem cell-derived bipotential gonadal-like cells towards a steroidogenic cell fate. | J Ovarian Res | 2023 | 37726790 | PubTator, text mining | PubMed |
| Zika virus targets human trophoblast stem cells and prevents syncytialization in placental trophoblast organoids. | Nat Commun | 2023 | 37684223 | PubTator, text mining | PubMed |
| Phenotypic and genotypic drug susceptibility patterns of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Central and Southern Ethiopia. | PLoS One | 2023 | 37682820 | PubTator, text mining | PubMed |
| Lineage classification and antitubercular drug resistance surveillance of Mycobacterium tuberculosis by whole-genome sequencing in Southern India. | Microbiol Spectr | 2023 | 37671895 | PubTator, text mining | PubMed |
| Combining Radiological and Genomic TB Portals Data for Drug Resistance Analysis. | IEEE Access | 2023 | 37663145 | PubTator, text mining | PubMed |
Phenotypic Drug Resistance Pattern and Mutation Characteristics of Mycobacterium tuberculosis from Different Body Fluids Among Extra Pulmonary Patients Presented in Selected Hospitals in Addis Ababa, Ethiopia. | Infect Drug Resist | 2023 | 37638071 | PubTator, text mining | PubMed |
| Prospective study on outcome of MDR-TB using the shorter regimen during COVID-19 pandemic. | J Family Med Prim Care | 2023 | 37636185 | PubTator, text mining | PubMed |
| Whole-Genome Sequencing to Predict Mycobacterium tuberculosis Drug Resistance: A Retrospective Observational Study in Eastern China. | Antibiotics (Basel) | 2023 | 37627677 | PubTator, text mining | PubMed |
| Isoniazid and Rifampicin Resistance-Conferring Mutations in Mycobacterium tuberculosis Isolates from South Africa. | Pathogens | 2023 | 37623975 | PubTator, text mining | PubMed |
| A Retrospective Analysis of Clinico-Demographic and Genetic Characteristics and Treatment Outcomes in Isoniazid Mono-Resistant Tuberculosis Patients: A Single-Center Study. | Cureus | 2023 | 37602046 | PubTator, text mining | PubMed |
| Delphi Survey on the Current and Future Korean Guidelines for Isoniazid-Monoresistant Tuberculosis. | Infect Drug Resist | 2023 | 37589016 | PubTator, text mining | PubMed |
| Treatment of drug-resistant tuberculosis in children and young adolescents in Brazil. | J Clin Tuberc Other Mycobact Dis | 2023 | 37588725 | PubTator, text mining | PubMed |
| Spermatogonial fate in mice with increased activin A bioactivity and testicular somatic cell tumours. | Front Cell Dev Biol | 2023 | 37564373 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3623/papers?page=7